PVR and neoplasm: Notably, IMiDs such as lenalidomide and pomalidomide are able to potentiate NK cell-mediated ADCC by increasing the expression of NK-cell activating ligands MICA and PVR/CD155 on MM cells, which facilitates tumor recognition and killing by NK cells [177].